Advanced search
Publication Cover
International Journal of General Medicine Volume 13, 2020 - Issue
Submit an article Journal homepage
158
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Golgi Protein 73 versus Alpha-Fetoprotein as a New Biomarker in Early Diagnosis of Hepatocellular Carcinoma

Omaima Mohamed Ali1 Internal Medicine Department, Faculty of Medicine, Aswan University, Aswan, Egypt
,
Hussein Ahmed El Amin2 Internal Medicine Department, Faculty of Medicine, Assuit University, Assuit, Egypt
,
Yousry Lotfy Sharkawy1 Internal Medicine Department, Faculty of Medicine, Aswan University, Aswan, Egypt
,
Adnan Ahmed Mohamed Ali3 Tropical Medicine and Gastroenterology Department, Faculty of Medicine, Assuit University, Assuit, Egypt
,
Emad Farah Mohammed Kholef4 Clinical Pathology Department, Faculty of Medicine, Aswan University, Aswan, EgyptORCID Iconhttps://orcid.org/0000-0002-1479-8653
ORCID Icon &
Wael Abd Elgwad Elsewify1 Internal Medicine Department, Faculty of Medicine, Aswan University, Aswan, EgyptCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4382-198X
ORCID Icon
Pages 193-200 | Published online: 18 May 2020

References

  • Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491. e471. doi:10.1053/j.gastro.2018.08.06530367835
  • Dimitroulis D, Damaskos C, Valsami S, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol. 2017;23(29):5282. doi:10.3748/wjg.v23.i29.528228839428
  • Ocker M. Biomarkers for hepatocellular carcinoma: what’s new on the horizon? World J Gastroenterol. 2018;24(35):3974. doi:10.3748/wjg.v24.i35.397430254402
  • Farag RMA, Al Ayobi D, et al. Studying the impact of Golgi protein 73 serving as a candidate biomarker in early diagnosis for hepatocellular carcinoma among Saudi patients. Asian Pac J Cancer Prev. 2019;20(1):215. doi:10.31557/APJCP.2019.20.1.21530678434
  • Liu P, Xie S-H, Hu S, et al. Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States. Oncotarget. 2017;8(40):68131.28978103
  • Westwood M, Joore M, Grutters J, et al. Contrast-enhanced ultrasound using SonoVue®(sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess. 2013;17(16):1.
  • Alswat KA, Sanai FM, Altuwaijri M, et al. Clinical characteristics of patients with hepatocellular carcinoma in a middle eastern population. Hepat Mon. 2013;13:5. doi:10.5812/hepatmon.7612
  • Carr BI, Akkiz H, Üsküdar O, et al. HCC with low-and normal-serum alpha-fetoprotein levels. Clin Pract. 2018;15(1):453.
  • Soresi M, Magliarisi C, Campagna P, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23(2C):1747–1753.12820452
  • Mehinovic L, Islamagic E, Husic-Selimovic A, Kurtovic-Kozaric A, Vukobrat-Bijedic Z, Suljevic D. Evaluation of diagnostic efficiency of alpha-fetoprotein in patients with liver cirrhosis and hepatocellular carcinoma: single-center experience. Open Access Maced J Med Sci. 2018;6(9):1668. doi:10.3889/oamjms.2018.34430337985
  • Ahn DG, Kim HJ, Kang H, et al. Feasibility of α-fetoprotein as a diagnostic tool for hepatocellular carcinoma in Korea. Korean J Intern Med. 2016;31(1):46. doi:10.3904/kjim.2016.31.1.4626767857
  • Durazo FA, Blatt LM, Corey WG, et al. Des‐γ‐carboxyprothrombin, α‐fetoprotein and AFP‐L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol. 2008;23(10):1541–1548. doi:10.1111/j.1440-1746.2008.05395.x18422961
  • Jiao C, Cui L, Piao J, Qi Y, Yu Z. Clinical significance and expression of serum Golgi protein 73 in primary hepatocellular carcinoma. J Cancer Res Ther. 2018;14(6):1239.30488837
  • Wang Y, Zhang Z, Zou D, et al. Serum Golgi protein 73 is a prognostic biomarker of liver transplantation patients. Int J Clin Exp Pathol. 2017;10(8):8626–8632.31966719
  • Yang J, Li J, Dai W, et al. Golgi protein 73 as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. Exp Ther Med. 2015;9(4):1413–1420. doi:10.3892/etm.2015.223125780444
  • Zhou Y, Yin X, Ying J, Zhang B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer. 2012;12(1):17. doi:10.1186/1471-2407-12-1722244200
  • AlSalloom AAM. An update of biochemical markers of hepatocellular carcinoma. Int J Health Sci. 2016;10(1):121. doi:10.12816/0031219
  • Marrero JA, Romano PR, Nikolaeva O, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43(6):1007–1012. doi:10.1016/j.jhep.2005.05.02816137783
  • Shi Y, Chen J, Li L, et al. A study of diagnostic value of golgi protein GP73 and its genetic assay in primary hepatic carcinoma. Technol Cancer Res Treat. 2011;10(3):287–294. doi:10.7785/tcrt.2012.50020521517136
  • Dai M, Chen X, Liu X, Peng Z, Meng J, Dai S. Diagnostic value of the combination of Golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: a meta-analysis. PLoS One. 2015;10(10):e0140067. doi:10.1371/journal.pone.014006726441340

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.